Israeli ADHD drug developer Alcobra files for a $17 million IPO

By Renaissance Capital,

Shutterstock photo

Alcobra, a biopharmaceutical company focused on the development of a drug to treat ADHD, filed on Monday with the SEC to raise up to $17 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2008 and has not yet generated any revenue, plans to list on the NASDAQ under the symbol ADHD. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ADHD

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by